Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2000

View Archived Issues

Sepracor completes large-scale U.S. efficacy study of (S)-zopiclone

Orally active ester prodrug of alphavbeta3 antagonist effective in rat model of osteoporosis

SmithKline Beecham to divest Kytril, Famvir and Vectavir/Denavir

Taxotere combination therapy approved in E.U. for treatment of advanced breast cancer

Novel treatment for asthma --an IL-4/IL-13 receptor antagonist-- characterized at ERS meeting

Ebselen as a new therapeutic agent for asthma

One-year treatment with UT-15 improves hemodynamics, exercise tolerance in PPH

ACS news: selective inhibitors of ICAM-1/E-selectin expression exerting antiinflammatory activity

XTL Biopharmaceuticals and Hybrigenics to codevelop novel HCV therapeutics

R&D at Pharmacia in the area of CETP inhibitors discussed at ACS meeting

Serono acquires exclusive rights to Cetrotide; U.S. launch planned

Noncompetitive dihydrophthalazine AMPA receptor antagonists synthesized at Annovis

Actelion continues development of tezosentan and bosentan as planned

ZD-6021: a potent, orally active tachykinin receptor antagonist

Phylos achieves key milestones in Amgen drug discovery collaboration

Supratek's SP-1017 shown to significantly increase gene expression

Aventis characterizes potential novel antiasthmatic agent

Sequenom and PHRI to develop high-speed diagnostic tests for MDR tuberculosis

Ortec's treatment for venous ulcers continues to demonstrate superiority

PARP inhibitors reportedly useful in combination with cytotoxic agents

Ranbaxy's new cell adhesion inhibitors with antiinflammatory activity

Amides with cholinergic activity and their use disclosed by Fujisawa

Endothelin receptor antagonists designed by Roche

MEK inhibitors and their use described in recent patents

DuPont patent describes new HIV protease inhibitors

New antitumor compound from Banyu produced by microorganism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...